Document is current
Any future updates will be listed below
-
Authors
Arctaedius, Isabelle https://orcid.org/0000-0001-7857-7393
Levin, Helena
Thorgeirsdóttir, Bergthóra
Moseby-Knappe, Marion
Cronberg, Tobias
Annborn, Martin
Nielsen, Niklas
Zetterberg, Henrik
Blennow, Kaj
Ashton, Nicholas J.
Frigyesi, Attila
Friberg, Hans
Lybeck, Anna
Mattsson-Carlgren, Niklas
-
Funding
Funding for this research was provided by:
Tegger Stiftelsen
Swedish National Health Service and Regional Research Support Region Skåne.
Segerfalk Foundation at Lund University and the Bundy Academy at Lund University
Government funding of clinical research within the Swedish National Health Services
Regional research support, Region Skane
Wallenberg Scholar supported by grants from the Swedish Research Council
European Union's Horizon Europe research and innovation programme
Alzheimer Drug Discovery Foundation
AD Strategic Fund and the Alzheimer's Association
Bluefield Project
the Olav Thon Foundation
Erling-Persson Family Foundation
Stiftelsen för Gamla Tjänarinnor
Hjärnfonden, Sweden
European Union Joint Programme – Neurodegenerative Disease Research
National Institute for Health and Care Research University College London Hospitals Biomedical Research Centre
UK Dementia Research Institute at UCL
Crafoord Foundation
Lions Skåne research grants
Skåne University Hospital grants
Swedish Heart and Lund Foundation
Hans‐Gabriel and Alice Trolle‐Wachtmeister Foundation for Medical Research
Maggie Stevens Foundation
fees for supervision of students from the Swedish National Health Services ALF via Lund University
Swedish Research Council
Familjen Rönnströms Stiftelse
Kockska Stiftelsen
WASP and DDLS Joint call for research projects
Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse
Swedish Alzheimer Foundation
Knut and Alice Wallenberg foundation
EU Joint Programme – Neurodegenerative Disease Research (2019-03401)
Lund University
- License Information
-
More Information
Article History
Received: 30 December 2023
Accepted: 23 March 2024
First Online: 9 April 2024
Declarations
:
: The Regional Ethical Review Board in Lund, Sweden, approved the study protocol (registration no. 2014/47 and 2022-02681-01). For patients who regained consciousness, written informed consent was obtained.
: Not applicable.
: HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Alzecure, Biogen, Cellectricon, Fujirebio, Lilly, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work).
